Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported Q1 EPS of $0.58, $0.36 worse than the analyst estimate of $0.94. Revenue for the quarter came in at $626 million versus the consensus estimate of $609.04 million.

For earnings history and earnings-related data on Regeneron Pharmaceuticals, Inc. (REGN) click here.